Biogen Inc

More Details of Biogen Inc Company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Company Info

Company codeBIIB

Company nameBiogen Inc

IPO dateSep 17, 1991

Founded at1997

CEOMr. Christopher A. (Chris) Viehbacher

Number of employees7605

Security typeOrdinary Share

Fiscal year-endSep 17

Address225 Binney Street

CityCAMBRIDGE

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02142

Phone17814642000

Websitehttps://www.biogen.com/

Company codeBIIB

IPO dateSep 17, 1991

Founded at1997

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

36.27K

+14.76%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

25.03K

+7.68%

Dr. Ginger Gregory, Ph.D.

Chief Human Resource Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.06K

+45.88%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

10.36K

-45.82%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

8.88K

+36.82%

Mr. Jesus B. Mantas

Independent Director

6.43K

+26.34%

Dr. Maria C. Freire, Ph.D.

Independent Director

3.48K

+62.47%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

1.90K

+187.01%

Name

Name/Position

Position

Shareholding

Change

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

36.27K

+14.76%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

25.03K

+7.68%

Dr. Ginger Gregory, Ph.D.

Chief Human Resource Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.06K

+45.88%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

10.36K

-45.82%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

By RegionUSD

Name

Revenue

Proportion

Rest of World

3.98B

41.09%

United States

3.30B

34.08%

United states-Revenues from anti-CD20 therapeutic

1.75B

18.09%

Rest of World-Other revenues

652.60M

6.74%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.39%

PRIMECAP Management Company

10.96%

BlackRock Institutional Trust Company, N.A.

5.87%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.37%

Other

63.35%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

11.39%

PRIMECAP Management Company

10.96%

BlackRock Institutional Trust Company, N.A.

5.87%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.37%

Other

63.35%

Type

Shareholder

Proportion

Investment Advisor

43.69%

Investment Advisor/Hedge Fund

36.85%

Hedge Fund

5.46%

Research Firm

2.82%

Pension Fund

2.29%

Bank and Trust

1.74%

Sovereign Wealth Fund

1.67%

Private Equity

0.35%

Individual Investor

0.15%

Other

4.99%

Institutional Shareholding

Update time: Mon, Jan 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

2074

138.81M

94.83%

-5.05M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

2022Q4

2292

132.00M

91.64%

-4.78M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

16.68M

11.39%

+1.13K

+0.01%

Dec 31, 2024

PRIMECAP Management Company

16.05M

10.96%

-268.87K

-1.65%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

8.59M

5.87%

+23.69K

+0.28%

Dec 31, 2024

State Street Global Advisors (US)

7.40M

5.05%

+53.29K

+0.73%

Dec 31, 2024

Wellington Management Company, LLP

4.93M

3.37%

-200.47K

-3.91%

Dec 31, 2024

Geode Capital Management, L.L.C.

3.70M

2.52%

+82.46K

+2.28%

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

3.10M

2.12%

-1.16M

-27.17%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

3.01M

2.06%

+40.53K

+1.36%

Feb 28, 2025

Pacer Advisors, Inc.

2.67M

1.82%

+2.65M

+13.57K%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

Invesco Biotechnology & Genome ETF

4.41%

iShares Neuroscience and Healthcare ETF

3.82%

Global X US Cash Flow Kings 100 ETF

3.55%

VanEck Biotech ETF

3.23%

Tema Neuroscience and Mental Health ETF

3.15%

Alger Russell Innovation ETF

3.04%

First Trust NYSE Arca Biotechnology Index Fund

2.94%

First Trust NASDAQ Pharmaceuticals ETF

2.89%

Invesco Pharmaceuticals ETF

2.39%

SPDR S&P Biotech ETF

2.19%

Invesco Biotechnology & Genome ETF

Proportion4.41%

iShares Neuroscience and Healthcare ETF

Proportion3.82%

Global X US Cash Flow Kings 100 ETF

Proportion3.55%

VanEck Biotech ETF

Proportion3.23%

Tema Neuroscience and Mental Health ETF

Proportion3.15%

Alger Russell Innovation ETF

Proportion3.04%

First Trust NYSE Arca Biotechnology Index Fund

Proportion2.94%

First Trust NASDAQ Pharmaceuticals ETF

Proportion2.89%

Invesco Pharmaceuticals ETF

Proportion2.39%

SPDR S&P Biotech ETF

Proportion2.19%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

118.840USD

Biogen Inc

118.840

Overview

Company